CARL (Carlsmed) Research & Development: $19.05 Mil (TTM As of Mar. 2026)


CARL Carlsmed Inc CARL
12 GF Score
Price $11.09
! 1 Warning Sign
View Full Analysis

What is Carlsmed Research & Development?

Carlsmed CARL +3.74% 12 Research & Development is $19.05 Mil as of Mar. 2026. GuruFocus rates CARL with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Carlsmed's Research & Development for the three months ended in Mar. 2026 was $5.18 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $19.05 Mil.

Carlsmed  (NAS:CARL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Carlsmed Research & Development Related Terms

Carlsmed Research & Development Historical Data

* Premium members only.

The historical data trend for Carlsmed's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carlsmed Research & Development Chart

Carlsmed Annual Data
Trend Dec23 Dec24 Dec25
Research & Development
7.40 14.30 17.02

Carlsmed Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.15 4.16 4.45 5.26 5.18
CARL
12GF Score
Carlsmed Inc CARL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carlsmed Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $19.05 Mil mean?
Carlsmed (CARL) has a Research & Development of $19.05 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Carlsmed and its competitors.
Is Carlsmed's Research & Development too high?
Carlsmed's current Research & Development is $19.05 Mil. Overall, Carlsmed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Carlsmed's Research & Development compare to SLP and SOPH?
Carlsmed's Research & Development of $19.05 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Carlsmed and its competitors. Carlsmed's current Research & Development is $19.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carlsmed stock overvalued right now?
Carlsmed (CARL) has a current Research & Development of $19.05 Mil. The current Research & Development is $19.05 Mil. Carlsmed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Carlsmed (CARL), the current Research & Development is $19.05 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Carlsmed Business Description

Other Exchanges I82:Germany
Address 1800 Aston Avenue, Suite 100, Carlsbad, CA, USA, 92008
Carlsmed Inc is a commercial-stage medical technology company focused on developing AI-enabled personalized solutions for spine surgery. The company operates as a single operating and reportable segment engaged in the design, manufacture, and marketing of its Aprevo technology platform, which provides customized surgical planning and implants for lumbar and cervical spine fusion procedures, mainly sold to hospitals and ambulatory surgical centers.
12GF Score

Get the complete analysis for CARL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.09
Price